-
1
-
-
84864285795
-
Position statement of the American diabetes association (ADA) and the European Association for the study of diabetes (EASD)
-
Management of hyperglycaemia in type 2 diabetes: A patientcentered approach
-
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patientcentered approach. Position statement of the American diabetes association (ADA) and the European Association for the study of diabetes (EASD). Diabetologia. 2012;55:1577-96.
-
(2012)
Diabetologia
, vol.55
, pp. 1577-1596
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
Diamant, M.4
Ferrannini, E.5
Nauck, M.6
-
2
-
-
2542576404
-
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes
-
Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-20.
-
(2004)
Diabetes
, vol.53
, pp. 1614-1620
-
-
Heise, T.1
Nosek, L.2
Ronn, B.B.3
Endahl, L.4
Heinemann, L.5
Kapitza, C.6
-
3
-
-
33746538357
-
Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart
-
Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med. 2006;23(8):879-86.
-
(2006)
Diabet Med
, vol.23
, Issue.8
, pp. 879-886
-
-
Ashwell, S.G.1
Gebbie, J.2
Home, P.D.3
-
4
-
-
25844511202
-
Early hypoglycaemia after accidental intramuscular injection of insulin glargine
-
Karges B, Boehm BO, Karges W. Early hypoglycaemia after accidental intramuscular injection of insulin glargine. Diabet Med. 2005;22(10):1444-5.
-
(2005)
Diabet Med
, vol.22
, Issue.10
, pp. 1444-1445
-
-
Karges, B.1
Boehm, B.O.2
Karges, W.3
-
6
-
-
84879558241
-
Diabetes Attitudes, Wishes and Needs second study (DAWN2™): Cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes
-
Nicolucci A, Kovacs Burns K, Holt RIG, Comaschi M, Hermanns N, Ishii H, et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2™): Cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes. Diabet Med. 2013;30(7):767-77.
-
(2013)
Diabet Med
, vol.30
, Issue.7
, pp. 767-777
-
-
Nicolucci, A.1
Kovacs, B.K.2
Holt, R.I.G.3
Comaschi, M.4
Hermanns, N.5
Ishii, H.6
-
7
-
-
84879589380
-
Diabetes Attitudes, Wishes and Needs second study (DAWN2™): Crossnational benchmarking indicators for family members living with people with diabetes
-
Kovacs Burns K, Nicolucci A, Holt RIG, Willaing I, Hermanns N, Kalra S, et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2™): crossnational benchmarking indicators for family members living with people with diabetes. Diabet Med. 2013;30(7):778-88.
-
(2013)
Diabet Med
, vol.30
, Issue.7
, pp. 778-788
-
-
Kovacs, B.K.1
Nicolucci, A.2
Holt, R.I.G.3
Willaing, I.4
Hermanns, N.5
Kalra, S.6
-
8
-
-
84859746575
-
Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec
-
Kurzhals P, Heise T, Strauss HM, Bøttcher SG, Granhall C, Haahr H, Jonassen I. Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec. Diabetes. 2011;60(Suppl 1):LB12.
-
(2011)
Diabetes
, vol.60
, Issue.SUPPL. 1
-
-
Kurzhals, P.1
Heise, T.2
Strauss, H.M.3
Bøttcher, S.G.4
Granhall, C.5
Haahr, H.6
Jonassen, I.7
-
9
-
-
82955198015
-
Insulin degludec is a new generation ultra-long acting basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential
-
Nishimura E, Rensen AO, Falckhansen BO, Stidsen C, Olsen GS, Schaumlffer L, et al. Insulin degludec is a new generation ultra-long acting basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential. American Diabetes Association (ADA) 70th Scientific Sessions: Abstract 1406-P.
-
American Diabetes Association (ADA) 70th Scientific Sessions: Abstract
, pp. 1406
-
-
Nishimura, E.1
Rensen, A.O.2
Falckhansen, B.O.3
Stidsen, C.4
Olsen, G.S.5
Schaumlffer, L.6
-
10
-
-
84859883969
-
Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine
-
Heise T, Hövelmann U, Nosek L, Bøttcher SG, Granhall C, Haahr H. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetes. 2011;60(Suppl 1):LB11.
-
(2011)
Diabetes
, vol.60
, Issue.SUPPL. 1
-
-
Heise, T.1
Hövelmann, U.2
Nosek, L.3
Bøttcher, S.G.4
Granhall, C.5
Haahr, H.6
-
11
-
-
84864375931
-
Insulin degludec: Four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
-
Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14: 859-64.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 859-864
-
-
Heise, T.1
Hermanski, L.2
Nosek, L.3
Feldman, A.4
Rasmussen, S.5
Haahr, H.6
-
12
-
-
79956110739
-
Insulin degludec in type 1 diabetes: Randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine
-
Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, et al. Insulin degludec in type 1 diabetes: randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care. 2011;34: 661-5.
-
(2011)
Diabetes Care
, vol.34
, pp. 661-665
-
-
Birkeland, K.I.1
Home, P.D.2
Wendisch, U.3
Ratner, R.E.4
Johansen, T.5
Endahl, L.A.6
-
13
-
-
79956136690
-
A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes: A randomized, controlled trial
-
Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011;34:669-74.
-
(2011)
Diabetes Care
, vol.34
, pp. 669-674
-
-
Heise, T.1
Tack, C.J.2
Cuddihy, R.3
Davidson, J.4
Gouet, D.5
Liebl, A.6
-
14
-
-
84869842163
-
Insulin degludec versus glargine in insulin naive patients with type 2 diabetes: A randomized treat to target trial (BEGIN Once Long)
-
Zinman B, Prillis-Tsimikar A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, et al. Insulin degludec versus glargine in insulin naive patients with type 2 diabetes: a randomized treat to target trial (BEGIN Once Long). Diabetes Care. 2012;35:2464-71.
-
(2012)
Diabetes Care
, vol.35
, pp. 2464-2471
-
-
Zinman, B.1
Prillis-Tsimikar, A.2
Cariou, B.3
Handelsman, Y.4
Rodbard, H.W.5
Johansen, T.6
-
15
-
-
84871937855
-
Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: A pre-planned meta-analysis of phase 3 trials
-
Ratner RE, Gough SCL, Mathieu C, Del Prato S, Bode B, Mersebach H, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175-84.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 175-184
-
-
Ratner, R.E.1
Gough, S.C.L.2
Mathieu, C.3
Del Prato, S.4
Bode, B.5
Mersebach, H.6
-
16
-
-
84874858316
-
Efficacy and safety of insulin degludec in a flexible dosing regimen vs. insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): A 26-week randomized, treat-totarget trial with a 26-week extension
-
Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs. insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-totarget trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98(3):1154-62.
-
(2013)
J Clin Endocrinol Metab
, vol.98
, Issue.3
, pp. 1154-1162
-
-
Mathieu, C.1
Hollander, P.2
Miranda-Palma, B.3
Cooper, J.4
Franek, E.5
Russell-Jones, D.6
-
17
-
-
84899847563
-
Insulin degludec given in a flexible once-daily dosing regimen does not compromise efficacy or safety in type 2 diabetes
-
Rana A, Meneghini L, Atkin S, Bain SC, Gough S, Raz I, et al. Insulin degludec given in a flexible once-daily dosing regimen does not compromise efficacy or safety in type 2 diabetes. Prim Care Diabetes 2013;7(1):85-85.
-
(2013)
Prim Care Diabetes
, vol.7
, Issue.1
, pp. 85
-
-
Rana, A.1
Meneghini, L.2
Atkin, S.3
Bain, S.C.4
Gough, S.5
Raz, I.6
-
18
-
-
49149121730
-
Management of hypothyroidism in adults
-
Vaidya B, Pearce SHS. Management of hypothyroidism in adults. BMJ 2008;337.
-
(2008)
BMJ
, pp. 337
-
-
Vaidya, B.1
Pearce, S.H.S.2
-
19
-
-
0026721384
-
Effect of "missed" pills on oral contraceptive effectiveness
-
Letterie GS, Chow GE. Effect of "missed" pills on oral contraceptive effectiveness. Obstet Gynecol. 1992;79:979-82.
-
(1992)
Obstet Gynecol
, vol.79
, pp. 979-982
-
-
Letterie, G.S.1
Chow, G.E.2
-
20
-
-
77952641591
-
What is the optimal therapy for young males with hypogonadotropic hypogonadism?
-
Han TS, Bouloux PM. What is the optimal therapy for young males with hypogonadotropic hypogonadism? Clin Endocrinol. 2010;72:731-7.
-
(2010)
Clin Endocrinol
, vol.72
, pp. 731-737
-
-
Han, T.S.1
Bouloux, P.M.2
-
21
-
-
84899855629
-
-
Available at, Accessed 27 Oct
-
FDA withholds insulin degludec approval; wants safety data. Available at: http://www.familypracticenews.com/news/diabetes-endocrinology-metabolism/single-article/fda-withholds-insulin-degludec-approval-wants-safety-data/db819817d382fd2744a59c04cad79c62.html. Accessed 27 Oct 2013.
-
(2013)
FDA Withholds Insulin Degludec Approval; Wants Safety Data
-
-
-
22
-
-
84886397925
-
Newer basal insulin analogues: Degludec, detemir, glargine
-
Kalra S. Newer basal insulin analogues: degludec, detemir, glargine. J Pak Med Ass. 2013;63(11): 1442-4.
-
(2013)
J Pak Med Ass
, vol.63
, Issue.11
, pp. 1442-1444
-
-
Kalra, S.1
|